"Designing Growth Strategies is in our DNA"

Middle East & Africa Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection {Intramuscular, Subcutaneous, and Intravenous}), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2023-2030

Region : Middle East | Format: PDF | Report ID: FBI107919



Play Audio Listen to Audio Version

The Middle East & Africa is expected to witness growth in the global multiple sclerosis drugs market. It is projected to grow at a CAGR of 5.7% during the forecast period. The global market for multiple sclerosis drugs is projected to grow from USD 22.32 billion in 2022 to USD 31.90 billion by 2030.

Multiple sclerosis is caused when the immune system damages the nerves' protective membrane, disrupting the body’s normal functioning. The increasing prevalence of the disease has been fueling the demand for multiple sclerosis drugs. Moreover, the improving public healthcare system along with the rising awareness regarding multiple sclerosis treatment in countries of the region is estimated to aid the growth of the Middle East& Africa. market

Our report on the Middle East & African market covers the following countries/regions – GCC, South Africa, and the rest of Middle East & Africa.


Increasing Use of Monoclonal Antibodies for the Disease Treatment to Fuel Market Growth

Incorporation of monoclonal antibodies for the treatment of the disease has been increased recently. This is due to increasing awareness about the efficiency of monoclonal antibodies in multiple sclerosis disease treatment. Sales of molecular antibody drugs, such as Lemtrada and Ocrevus, have been increasing significantly.

Therefore, the increasing penetration of molecular antibody multiple sclerosis drugs has been fueling the Middle East & Africa multiple sclerosis drugs market growth.


Market Players’ Increasing Focus on Commercialization of MS Drugs in the Region to Fuel Market Growth

Market players have increased their focus on the commercialization of multiple sclerosis drugs in the region to increase the accessibility of effective treatment to patients.

  • For instance, in April 2018, Merck KGaA, announced the registration approval of MAVENCLAD (cladribine tablets) by United Arab Emirates Ministry of Health and Prevention indicated to adult patients with active relapsing Multiple Sclerosis (MS). With this approval, MAVENCLAD became the first drug approved in the Middle East & Africa, and the UAE became the first country in the region for the approval. The approval was directed by the Ministry of Health and Prevention, with an aim to improve healthcare services in the country.

The commercialization of these drugs has been fueling the market growth in the region.


High Cost Associated with the Disease Treatment through Drugs to Limit the Market Growth

Prevalence of the disease has been increasing significantly, which has been elevating the demand for effective treatment. However, high cost associated with the overall treatment through for multiple sclerosis drugs tends to limit the market growth.

Furthermore, due to the limitations associated with diagnosis of the disease, many times the patients are not aware about their disease. Due to this, they do not get accurate treatment. Such factors tend to limit the market growth.


Based on the Middle East & Africa multiple sclerosis drugs market share, Biogen, Novartis AG, and F. Hoffman-La Roche Ltd. are significant players operating in the market. The growth of these players is due to the strong product portfolio of these companies. 

Other players, such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Bristol-Myers Squibb Company, have increased their focus on mergers and acquisitions to strengthen their position in the market.


  • Biogen (U.S.)

  • Pfizer Inc. (U.S.)

  • F. Hoffmann-La Roche Ltd. (Switzerland)

  • Novartis AG (Switzerland)

  • Merck & Co., Inc. (U.S.)

  • Sanofi (France)

  • Teva Pharmaceutical Industries Ltd. (Israel)

  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation) (New Jersey)

  • Bristol-Myers Squibb Company (U.S.)


  • February 2018: Merck announced that the Argentinian Administration of Medicines, Food and Medical Technology (ANMAT) approved the registration of MAVENCLAD (cladribine tablets) for the treatment of adult patients with highly active relapsing Multiple Sclerosis (MS) as defined by clinical or imaging features. This marked the first approval for MAVENCLAD in Latin America and following local regulatory processes.

  • February 2018: Bayer announced the introduction of self-injecting device to help the growing number of multiple sclerosis patients in the Middle East. Bayer stated that it was an auto-injector and would be the first component of an innovative dose delivery system for MS.


To gain extensive insights into the market, Request for Customization

The research report provides qualitative and quantitative insights on the market and a detailed analysis of the market size & growth rate for all possible segments in the market. Along with the market forecast, the research report provides an elaborative analysis of the market dynamics and competitive landscape. Various key insights presented in the report are overview of the prevalence of the disease, pipeline analysis, new product launches, and key industry developments – mergers, acquisitions & partnerships, and the impact of COVID-19 pandemic on the market.

Report Scope & Segmentation



Study Period


Base Year


Estimated Year


Forecast Period


Historical Period


Growth Rate

CAGR of 5.7% from 2023 to 2030


Value (USD Billion)


Drug Class; Route of Administration; Distribution Channel; and Country/Sub-Region

By Drug Class

  • Immunomodulators

  • Immunosuppressants

  • Interferons

  • Others

By Route of Administration

  • Oral

  • Injection

    • Intramuscular

    • Subcutaneous

    • Intravenous

By Distribution Channel

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

By Country/ Sub-Region

  • GCC

  • South Africa

  • Rest of Middle East & Africa

Frequently Asked Questions

Growing at a CAGR of 5.7%, the market will exhibit steady growth in the forecast period (2023-2030).

Increasing prevalence of multiple sclerosis and emphasis of market players on the launch of drugs in the region are fueling the market growth.

Biogen, Novartis AG, F. Hoffman-La Roche Ltd., and Sanofi are the major market players in the Middle East & Africa market.

South Africa dominated the market in 2022.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • Aug, 2023
  • 2022
  • 2019-2021
  • 109


  • $3850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- UGlobal hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.